Skip to main content
. Author manuscript; available in PMC: 2023 Jun 22.
Published in final edited form as: Nat Med. 2023 Jan 31;29(3):623–631. doi: 10.1038/s41591-023-02241-7

Table A5.

Determinants of early, late and non-vaccination: a separate analysis by using individual health measures in 2018

Multinomial logit regression
Dep. variable with three outcomes (one used as the base outcome)
Phase 1 vaccination from Jan 2021 to summer 2021 vs. unvaccinated Phase 2 vaccination from summer 2021 to summer 2022 vs. unvaccinated Phase 2 vaccination vs. phase 1 vaccination
(1) (2) (3)
n=9890 n=9890 n=9890
RRR (95% CI) p value RRR (95% CI) p value RRR (95% CI) p value
Female 195.00 (0.70–1.00) 66.000 0.85 (0.70–1.02) 0.081 1.01 (0.90–1.13) 0.850
Married 28.00 (1.38–2.01) 10.000 1.39 (1.13–1.70) 0.001 0.83 (0.73–0.95) 0.008
Ethnic minorities 6.00 (0.44–0.84) 2.000 1.42 (1.02–1.98) 0.037 2.35 (1.95–2.84) 0.000
Urban Hukou 184.00 (0.46–0.68) 57.000 0.39 (0.31–0.49) 0.000 0.70 (0.60–0.83) 0.000
Age group (ref. 52–59)
 Age 60–69 44.00 (0.74–1.18) 9.000 2.07 (1.58–2.72) 0.000 2.22 (1.88–2.61) 0.000
 Age 70–79 114.00 (0.49–0.80) 28.000 2.21 (1.67–2.91) 0.000 3.51 (2.96–4.15) 0.000
 Age 80+ 340.00 (0.13–0.22) 34.000 1.54 (1.14–2.09) 0.005 9.07 (7.34–11.21) 0.000
Education (ref. illiterate)
 Primary school (literate) 0.06 (0.88–1.30) 0.077 1.03 (0.84–1.27) 0.767 0.97 (0.85–1.10) 0.611
 Middle and high school + 0.01 (0.92–1.49) 0.012 0.90 (0.69–1.17) 0.422 0.77 (0.65–0.90) 0.001
Region (ref. East)
 Central 0.05 (0.73–1.07) 0.067 0.98 (0.79–1.20) 0.823 1.10 (0.96–1.26) 0.159
 West 0.30 (1.11–1.69) 0.185 1.58 (1.26–1.98) 0.000 1.15 (1.01–1.32) 0.037
 Northeast 0.01 (0.77–1.47) 0.011 2.02 (1.43–2.84) 0.000 1.90 (1.55–2.31) 0.000
Functionally dependent 0.03 (0.34–0.50) 0.033 0.64 (0.52–0.78) 0.000 1.55 (1.35–1.78) 0.000
Chronic conditions
 Hypertension 0.08 (0.60–0.85) 0.064 0.92 (0.76–1.10) 0.347 1.28 (1.14–1.44) 0.000
 Heart diseases 0.74 (0.61–0.90) 0.002 0.78 (0.63–0.97) 0.022 1.06 (0.92–1.22) 0.436
 Stroke 0.60 (0.46–0.79) 0.000 0.85 (0.64–1.13) 0.256 1.41 (1.15–1.72) 0.001
 Diabetes 0.79 (0.63–0.99) 0.043 0.97 (0.76–1.24) 0.815 1.23 (1.05–1.45) 0.012
 Lung diseases 0.75 (0.60–0.95) 0.017 0.81 (0.63–1.04) 0.104 1.08 (0.92–1.27) 0.353
 Cancer 0.29 (0.20–0.43) 0.000 0.39 (0.25–0.62) 0.000 1.35 (0.92–1.99) 0.129
 Dyslipidaemia 1.01 (0.82–1.23) 0.937 0.94 (0.75–1.17) 0.588 0.93 (0.81–1.08) 0.343
 Liver diseases 1.29 (0.91–1.83) 0.153 1.43 (0.98–2.07) 0.062 1.11 (0.89–1.37) 0.363
 Kidney diseases 0.96 (0.73–1.26) 0.747 0.81 (0.60–1.10) 0.174 0.85 (0.70–1.03) 0.105
 Asthma 0.77 (0.55–1.08) 0.135 0.83 (0.58–1.19) 0.308 1.07 (0.84–1.37) 0.584
 Arthritis/rheumatism 1.59 (1.33–1.90) 0.000 1.27 (1.05–1.53) 0.014 0.80 (0.71–0.90) 0.000
 Digestive disease 1.12 (0.93–1.35) 0.215 1.00 (0.82–1.21) 0.965 0.89 (0.78–1.00) 0.052
Constant 14.57 (10.21–20.80) 0.000 1.67 (1.12–2.48) 0.011 0.11 (0.09–0.15) 0.000

Note: Health measures, including functional dependency and chronic disease incidence, were from the 2018 wave. Standard errors are clustered at the household level. RRR stands for relative risk ratio. Phase 1 is from January 2021 to July 2021, the early period when the vaccination had not been available for more than 6 months; Phase 2, from September 2021 to July 2022, is the later period. Main column (3) only changed the base outcome, so the RRRs were quotients between those from column (2) and column (1). Summer is the survey season of CHARLS, mostly spanning from July to August.